Capricor Therapeutics logo

Capricor TherapeuticsNASDAQ: CAPR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 February 2007

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$823.01 M
-17%vs. 3y high
72%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
93%vs. sector
-65%vs. 3y high
89%vs. sector

Price

after hours | Wed, 20 Nov 2024 00:56:41 GMT
$18.10-$0.90(-4.74%)

Dividend

No data over the past 3 years
$2.26 M$8.65 M
$2.26 M-$12.56 M

Analysts recommendations

Institutional Ownership

CAPR Latest News

Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
zacks.com13 November 2024 Sentiment: NEGATIVE

Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago.

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
zacks.com05 November 2024 Sentiment: NEGATIVE

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
globenewswire.com18 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares to cover over allotments, bringing the total gross proceeds to Capricor from the offering to approximately $86.3 million, before deducting underwriting commissions and other offering expenses payable by Capricor. All of the shares of common stock sold in the offering, including the over-allotment, were offered by Capricor. The closing of the offering occurred on October 18, 2024.

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
globenewswire.com17 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its underwritten offering of 4,412,000 shares of common stock at a public offering price of $17.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 661,800 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October 18, 2024, subject to the satisfaction of customary closing conditions.

Capricor Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com16 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
globenewswire.com09 October 2024 Sentiment: POSITIVE

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
benzinga.com01 October 2024 Sentiment: POSITIVE

Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.

Capricor Therapeutics is up over 100%, Could Rise Even Higher
marketbeat.com30 September 2024 Sentiment: POSITIVE

Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.

Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More
247wallst.com29 September 2024 Sentiment: NEUTRAL

24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued.

Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
seekingalpha.com24 September 2024 Sentiment: POSITIVE

BLA submission of deramiocel for treatment of patients with DMD cardiomyopathy is expected in October 2024, with the completed portion expected before the end of 2024. The Duchenne Muscular Dystrophy drugs market size is projected to reach $5.5 billion by 2032. There is potential to eventually expand the label of deramiocel with positive results from Cohort A and Cohort B of the Phase 3 HOPE-3 study to target DMD skeletal muscle myopathy patients.

  • 1(current)

What type of business is Capricor Therapeutics?

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

What sector is Capricor Therapeutics in?

Capricor Therapeutics is in the Healthcare sector

What industry is Capricor Therapeutics in?

Capricor Therapeutics is in the Biotechnology industry

What country is Capricor Therapeutics from?

Capricor Therapeutics is headquartered in United States

When did Capricor Therapeutics go public?

Capricor Therapeutics initial public offering (IPO) was on 13 February 2007

What is Capricor Therapeutics website?

https://www.capricor.com

Is Capricor Therapeutics in the S&P 500?

No, Capricor Therapeutics is not included in the S&P 500 index

Is Capricor Therapeutics in the NASDAQ 100?

No, Capricor Therapeutics is not included in the NASDAQ 100 index

Is Capricor Therapeutics in the Dow Jones?

No, Capricor Therapeutics is not included in the Dow Jones index

When was Capricor Therapeutics the previous earnings report?

No data

When does Capricor Therapeutics earnings report?

The next expected earnings date for Capricor Therapeutics is 28 February 2025